HIGHLIGHTS
- who: Smith and collaborators from the This Article was downloaded from Harvard University's DASH repository, and is made available Hamburg, Germany have published the research: Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis, in the Journal: (JOURNAL)
- what: Our study does not support the use of plasma S100β as a biomarker for tumor burden in neurofibromatosis.
- how: The authors analyzed blood samples from 127 consecutive patients enrolled in the research study at Massachusetts General Hospital.
- future: Work is needed to identify a reliable biomarker to screen . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.